PB1805: INSIGHTS FROM ORAL AZACITIDINE EARLY ACCESS PROGRAM IN FRANCE: PATIENT POPULATION WITH ACUTE MYELOID LEUKEMIA RECEIVING ORAL-AZA FOR MAINTENANCE OF COMPLETE REMISSION AFTER INDUCTION CHEMOTHERAPY

• E. Raffoux,
• S. De Botton,
• L. Ades,
• M. Carré,
• T. Cluzeau,
• C. Saillard,
• M. Heiblig,
• F. Beckerich,
• L. Gastaud,
• A. Dupuis,
• U. Richez,
• P.-Y. Dumas

Affiliations

E. Raffoux

1 Hematology, APHP St-Louis, Paris

S. De Botton

2 Hematology, Gustave Roussy, Villejuif

L. Ades

1 Hematology, APHP St-Louis, Paris

M. Carré

3 Hematology, Grenoble Alpes University Hospital, Grenoble

T. Cluzeau

4 Hematology, Nice University Hospital, Nice

C. Saillard

5 Hematology, Institut Paoli Calmettes, Marseille

M. Heiblig

6 Hematology, Lyon Sud hospital, Lyon

F. Beckerich

7 Hematology, Henry Mondor hospital, Créteil

L. Gastaud

8 Medical Oncology, Centre Lacassagne, Nice

A. Dupuis

9 Medical, Bristol Myers Squibb, Rueil Malmaison

U. Richez

9 Medical, Bristol Myers Squibb, Rueil Malmaison

P.-Y. Dumas

10 Hematology, Haut-Leveque-Bordeaux University Hospital, Bordeaux, France